International Prognostic Scoring System IPSS

• Uses BM blast %, BM cytogenetics and number of cytopenias to compute a risk score and stratify patients into 4 distinct groups.

• Improved prognostic power for both survival and evolution into AML compared with earlier systems.

• Analysis excluded CMML with a WBC >12 x 109/L as this was considered myeloproliferative rather than MDS.

• IPSS score should be calculated during a stable clinical state not, for example, during florid infective initial presentation.

• May be used to assist management decisions.

0 0

Post a comment